Galmed Pharmaceuticals
Business Services · Israel · 1-10 Employees
View Company Info for Free
Overview
Headquarters
16 Abba Hillel Silver Rd, Ramat Gan, Tel...Phone Number
+972 36938448Website
www.galmedpharma.comRevenue
-Stock Symbol
GLMDIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About Galmed Pharmaceuticals
Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for liver, metabolic, and inflammatory diseases. Founded in 2000 and headquartered in Israel, the company operates within the healthcare and biotechnology sector, with a strong emphasis on addressing conditions that currently have limited treatment options. Galmed’s lead drug candidate is Aramchol, a first-in-class synthetic fatty acid–bile acid conjugate designed to target liver diseases, particularly non-alcoholic steatohepatitis (NASH) and fibrosis. This oral therapy is currently being evaluated in advanced clinical trials, including Phase III studies, highlighting its potential as a novel treatment for patients with metabolic disorders linked to obesity and diabetes. In addition to Aramchol, the company is developing other pipeline products such as Amilo-5MER, a synthetic peptide aimed at treating inflammatory conditions, and MyBiotics, which is in preclinical develoRead more
Galmed Pharmaceuticals Org Chart
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Galmed Pharmaceuticals your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check if Galmed Pharmaceuticals has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at Galmed Pharmaceuticals
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Product Launch: Get notified when Galmed Pharmaceuticals launches new products
Funding: Get notified immidiatlly once Galmed Pharmaceuticals has new funding data
Earning: See what the market has to say on Galmed Pharmaceuticals recently announced quarterly report
Galmed Pharmaceuticals, which may be a good buyer, showed buying intent in Masked Content Topic
Check out if Galmed Pharmaceuticals is spiking on competitors!
Click to see if Galmed Pharmaceuticals had a recent Job posting/layoffs
Website visits: Recent activity has been detected on your website
Recommended Actions
Find VP level buyers at Galmed Pharmaceuticals
Find 3 more new buyers
Company Profile Activity
Activity Insights
Galmed Pharmaceuticals is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Galmed Pharmaceuticals is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Galmed Pharmaceuticals.
Galmed Pharmaceuticals financials insights
Gather financial insights about Galmed Pharmaceuticals, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2014
Stock Offering
$38.3M
2021
Stock Offering
$18.4M
Galmed Pharmaceuticals Tech Stack
A closer look at the technologies used by Galmed Pharmaceuticals
Most Recent Scoops
Mergers & Acquisitions (M&A)
Mergers & Acquisitions, Acquisitions, Mergers
Project
Laboratory Operations, Medical Research, Clinical Operations
Earnings
Earnings, Finance
Earnings
Earnings, Finance
Person-Based
Galmed Pharmaceuticals News & Media
Galmed Announces First Time Results in Prostate Oncology Studies: Aramchol Demonstrates 3-4 Fold Increase in Cell Death Compared to Enzalutamide (XTANDI®) Alone in Prostate Cancer Models
Xtandi® (enzalutamide) is indicated as monotherapy for the treatment of patients with non-metastatic prostate cancer (nmCSPC) at high risk of metastasis and for the treatment of patients with metastatic prostate cancer (mCSPC) who are maintaining treatment with a GnRH analogue. Global...Galmed Announces Breakthrough Development of Dispersible Film Delivery (ODF), Brain Penetrating formulation of its SCD1 inhibitor Aramchol for Parkinson's Disease, Targeting $6 Billion Market
Aramchol meglumine is the only SCD1 inhibitor with an established clinical safety profile and confirmed blood-brain barrier (BBB) penetration. In order to improve patient convenience and long-term treatment adherence by Parkinson patients affected by dysphagia, an ODF formulation was...Galmed Announces the Breakthrough Development of Novel LNP Cardiac Targeted Formulation of its SCD1 inhibitor, Aramchol
Galmed has developed, in collaboration with Barcode Nanotech, a unique proprietary lipid nanoparticles (LPNs) novel formulation of Aramchol that penetrates the heart tissue and redirects Aramchol's biodistribution away from liver-hepatocytes to the heart's muscle. Cardiac fibrosis is a...Galmed Pharmaceuticals Ltd. Announces Restructured Acquisition Terms for Colospan Ltd ...
Colospan Ltd. ("Colospan") provides Galmed Pharmaceuticals Ltd. ("Galmed") (NASDAQ: GLMD) with a commercially ready product in the EU/Israel (CE marked under...
Read more news
Top Business Services Companies
Frequently Asked Questions Regarding Galmed Pharmaceuticals
Sign Up For FreeTo access detailed company insights
Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for liver, metabolic, and inflammatory diseases. Founded in 2000 and headquartered in Israel, the company operates within the healthcare and biotechnology sector, with a strong emphasis on addressing conditions that currently have li... Read More
